Indoleamine-2,3-dioxygenase-2 (IDO2) can also be therapeutically targeted to catalyze the conversion of tryptophan to canine urine; this target is upregulated in gliomas and other types of cancer (Mondanelli et al., 2021). The gene discussed is IDO2; the disease is central nervous system cancer.